{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:15:27Z","timestamp":1791908127886,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T00:00:00Z","timestamp":1600473600000},"content-version":"vor","delay-in-days":2394,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1074\/jbc.m113.506394","type":"journal-article","created":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T03:13:37Z","timestamp":1390446817000},"page":"6908-6920","source":"Crossref","is-referenced-by-count":35,"title":["LT175 Is a Novel PPAR\u03b1\/\u03b3 Ligand with Potent Insulin-sensitizing Effects and Reduced Adipogenic Properties"],"prefix":"10.1016","volume":"289","author":[{"given":"Federica","family":"Gilardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Giudici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Mitro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Maschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uliano","family":"Guerrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"Rando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Cermenati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Laghezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Loiodice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Pochetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lavecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"De Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krister","family":"Bamberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Crestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1074\/jbc.M113.506394_bib1","doi-asserted-by":"crossref","first-page":"7768","DOI":"10.1021\/jm800733h","article-title":"Crystal structure of the peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) ligand binding domain complexed with a novel partial agonist. A new region of the hydrophobic pocket could be exploited for drug design","volume":"51","author":"Montanari","year":"2008","journal-title":"J. Med. Chem"},{"key":"10.1074\/jbc.M113.506394_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(11)60679-X","article-title":"National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980. Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2\u20137 million participants","volume":"378","author":"Danaei","year":"2011","journal-title":"Lancet"},{"key":"10.1074\/jbc.M113.506394_bib3","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nm1278","article-title":"Thiazolidinediones expand body fluid volume through PPAR\u03b3 stimulation of ENaC-mediated renal salt absorption","volume":"11","author":"Guan","year":"2005","journal-title":"Nat. Med"},{"key":"10.1074\/jbc.M113.506394_bib4","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD). A multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"10.1074\/jbc.M113.506394_bib5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jcb.21994","article-title":"PPAR\u03b32 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells","volume":"106","author":"Shockley","year":"2009","journal-title":"J. Cell. Biochem"},{"key":"10.1074\/jbc.M113.506394_bib6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.cmet.2010.04.015","article-title":"PGC1\u03b1 mediates PPAR\u03b3 Activation of osteoclastogenesis and rosiglitazone-induced bone loss","volume":"11","author":"Wei","year":"2010","journal-title":"Cell Metab"},{"key":"10.1074\/jbc.M113.506394_bib7","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/S0140-6736(08)61628-1","article-title":"Rosiglitazone no longer recommended","volume":"372","author":"Lancet","year":"2008","journal-title":"Lancet"},{"key":"10.1074\/jbc.M113.506394_bib8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0140-6736(09)60870-9","article-title":"Effect of the dual peroxisome proliferator-activated receptor-\u03b1\/\u03b3 agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY). A phase II, randomised, dose-ranging study","volume":"374","author":"Henry","year":"2009","journal-title":"Lancet"},{"key":"10.1074\/jbc.M113.506394_bib9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.coph.2006.06.009","article-title":"PPAR\u03b1 and PPAR\u03b3 dual agonists for the treatment of type 2 diabetes and the metabolic syndrome","volume":"6","author":"Fi\u00e9vet","year":"2006","journal-title":"Curr. Opin. Pharmacol"},{"key":"10.1074\/jbc.M113.506394_bib10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1210\/me.2005-0171","article-title":"A novel partial agonist of peroxisome proliferator-activated receptor-\u03b3 (PPAR\u03b3) recruits PPAR\u03b3-coactivator-1\u03b1, prevents triglyceride accumulation, and potentiates insulin signaling in vitro","volume":"20","author":"Burgermeister","year":"2006","journal-title":"Mol. Endocrinol"},{"key":"10.1074\/jbc.M113.506394_bib11","doi-asserted-by":"crossref","first-page":"9168","DOI":"10.1074\/jbc.M800104200","article-title":"T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor \u03b3 binding properties","volume":"283","author":"Li","year":"2008","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M113.506394_bib12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR\u03b3 by Cdk5","volume":"466","author":"Choi","year":"2010","journal-title":"Nature"},{"key":"10.1074\/jbc.M113.506394_bib13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature10383","article-title":"Antidiabetic actions of a non-agonist PPAR\u03b3 ligand blocking Cdk5-mediated phosphorylation","volume":"477","author":"Choi","year":"2011","journal-title":"Nature"},{"key":"10.1074\/jbc.M113.506394_bib14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cell.2011.09.050","article-title":"Adipocyte NCoR knockout decreases PPAR\u03b3 phosphorylation and enhances PPAR\u03b3 activity and insulin sensitivity","volume":"147","author":"Li","year":"2011","journal-title":"Cell"},{"key":"10.1074\/jbc.M113.506394_bib15","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1021\/jm9013899","article-title":"Structural insight into peroxisome proliferator-activated receptor \u03b3 binding of two ureidofibrate-like enantiomers by molecular dynamics, cofactor interaction analysis, and site-directed mutagenesis","volume":"53","author":"Pochetti","year":"2010","journal-title":"J. Med. Chem"},{"key":"10.1074\/jbc.M113.506394_bib16","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1210\/me.2002-0036","article-title":"A new selective peroxisome proliferator-activated receptor \u03b3 antagonist with antiobesity and antidiabetic activity","volume":"16","author":"Rieusset","year":"2002","journal-title":"Mol. Endocrinol"},{"key":"10.1074\/jbc.M113.506394_bib17","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/me.2006-0152","article-title":"A novel peroxisome proliferator-activated receptor responsive element-luciferase reporter mouse reveals gender specificity of peroxisome proliferator-activated receptor activity in liver","volume":"21","author":"Ciana","year":"2007","journal-title":"Mol. Endocrinol"},{"key":"10.1074\/jbc.M113.506394_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1021\/jm201306q","article-title":"Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity","volume":"55","author":"Porcelli","year":"2012","journal-title":"J. Med. Chem"},{"key":"10.1074\/jbc.M113.506394_bib19","doi-asserted-by":"crossref","first-page":"732","DOI":"10.2337\/db12-0548","article-title":"Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue","volume":"62","author":"Galmozzi","year":"2013","journal-title":"Diabetes"},{"key":"10.1074\/jbc.M113.506394_bib20","first-page":"219","article-title":"Peroxisome Proliferator-Activated Receptors (PPARs)","author":"Mitro","year":"2013"},{"key":"10.1074\/jbc.M113.506394_bib21","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/j.1742-1241.2006.01128.x","article-title":"Thiazolidinediones, insulin resistance and obesity. Finding a balance","volume":"60","author":"Wilding","year":"2006","journal-title":"Int. J. Clin. Pract"},{"key":"10.1074\/jbc.M113.506394_bib22","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1124\/mol.107.042689","article-title":"In vivo imaging reveals selective peroxisome proliferator activated receptor modulator activity of the synthetic ligand 3-(1-(4-chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid (MK-886)","volume":"73","author":"Biserni","year":"2008","journal-title":"Mol. Pharmacol"},{"key":"10.1074\/jbc.M113.506394_bib23","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI118687","article-title":"Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice","volume":"97","author":"Berthou","year":"1996","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.M113.506394_bib24","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.2337\/diacare.26.11.3148","article-title":"Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity","volume":"26","author":"Shadid","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1074\/jbc.M113.506394_bib25","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1194\/jlr.M500294-JLR200","article-title":"Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans","volume":"46","author":"Cinti","year":"2005","journal-title":"J. Lipid Res"},{"key":"10.1074\/jbc.M113.506394_bib26","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1172\/JCI6223","article-title":"Peroxisome proliferator-activated receptor \u03b1 mediates the adaptive response to fasting","volume":"103","author":"Kersten","year":"1999","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.M113.506394_bib27","doi-asserted-by":"crossref","first-page":"9406","DOI":"10.1073\/pnas.0501744102","article-title":"Collecting duct-specific deletion of peroxisome proliferator-activated receptor \u03b3 blocks thiazolidinedione-induced fluid retention","volume":"102","author":"Zhang","year":"2005","journal-title":"Proc. Natl. Acad. Sci"},{"key":"10.1074\/jbc.M113.506394_bib28","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4158\/EP.9.5.406","article-title":"Thiazolidinediones, peripheral edema, and type 2 diabetes. Incidence, pathophysiology, and clinical implications","volume":"9","author":"Mudaliar","year":"2003","journal-title":"Endocr. Pract"},{"key":"10.1074\/jbc.M113.506394_bib29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/01.RES.0000179226.34112.6d","article-title":"Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-\u03b3 both induce cardiac hypertrophy in mice","volume":"97","author":"Duan","year":"2005","journal-title":"Circ. Res"},{"key":"10.1074\/jbc.M113.506394_bib30","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1161\/01.CIR.0000012467.61045.87","article-title":"Adaptation and maladaptation of the heart in diabetes. Part II. Potential mechanisms","volume":"105","author":"Young","year":"2002","journal-title":"Circulation"},{"key":"10.1074\/jbc.M113.506394_bib31","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/CIRCULATIONAHA.109.888735","article-title":"Rescue of cardiomyopathy in peroxisome proliferator-activated receptor-\u03b1 transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferator-activated receptor-\u03b1 activators","volume":"121","author":"Duncan","year":"2010","journal-title":"Circulation"},{"key":"10.1074\/jbc.M113.506394_bib32","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.M113.506394_bib33","doi-asserted-by":"crossref","first-page":"e1000154","DOI":"10.1371\/journal.pmed.1000154","article-title":"The risk of fractures associated with thiazolidinediones. A self-controlled case-series study","volume":"6","author":"Douglas","year":"2009","journal-title":"PLoS Med"},{"key":"10.1074\/jbc.M113.506394_bib34","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archinternmed.2010.207","article-title":"Rosiglitazone revisited. An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality","volume":"170","author":"Nissen","year":"2010","journal-title":"Arch. Intern. Med"},{"key":"10.1074\/jbc.M113.506394_bib35","doi-asserted-by":"crossref","first-page":"16906","DOI":"10.1074\/jbc.M200585200","article-title":"Overexpression and ribozyme-mediated targeting of transcriptional coactivators CREB-binding protein and p300 revealed their indispensable roles in adipocyte differentiation through the regulation of peroxisome proliferator-activated receptor \u03b3","volume":"277","author":"Takahashi","year":"2002","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M113.506394_bib36","doi-asserted-by":"crossref","first-page":"25281","DOI":"10.1074\/jbc.C300175200","article-title":"Transcriptional coactivator PRIP, the peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3)-interacting protein, is required for PPAR\u03b3-mediated adipogenesis","volume":"278","author":"Qi","year":"2003","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M113.506394_bib37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.cmet.2011.05.012","article-title":"Thiazolidinediones regulate adipose lineage dynamics","volume":"14","author":"Tang","year":"2011","journal-title":"Cell Metab"},{"key":"10.1074\/jbc.M113.506394_bib38","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cell.2012.02.017","article-title":"Mechanisms for insulin resistance. Common threads and missing links","volume":"148","author":"Samuel","year":"2012","journal-title":"Cell"},{"key":"10.1074\/jbc.M113.506394_bib39","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.cmet.2007.05.002","article-title":"Hepatic fibroblast growth factor 21 is regulated by PPAR\u03b1 and is a key mediator of hepatic lipid metabolism in ketotic states","volume":"5","author":"Badman","year":"2007","journal-title":"Cell Metab"},{"key":"10.1074\/jbc.M113.506394_bib40","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","article-title":"Endocrine regulation of the fasting response by PPAR\u03b1-mediated induction of fibroblast growth factor 21","volume":"5","author":"Inagaki","year":"2007","journal-title":"Cell Metab"},{"key":"10.1074\/jbc.M113.506394_bib41","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.1021\/pr400587y","article-title":"Metabonomic profiling revealed an alteration in purine nucleotide metabolism associated with cardiac hypertrophy in rats treated with thiazolidinediones","volume":"12","author":"Liu","year":"2013","journal-title":"J. Proteome Res"},{"key":"10.1074\/jbc.M113.506394_bib42","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","article-title":"Fibroblast growth factor 21 corrects obesity in mice","volume":"149","author":"Coskun","year":"2008","journal-title":"Endocrinology"},{"key":"10.1074\/jbc.M113.506394_bib43","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.cmet.2013.04.005","article-title":"Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice","volume":"17","author":"Lin","year":"2013","journal-title":"Cell Metab"},{"key":"10.1074\/jbc.M113.506394_bib44","doi-asserted-by":"crossref","first-page":"10853","DOI":"10.1073\/pnas.0904187106","article-title":"FGF21 induces PGC-1\u03b1 and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response","volume":"106","author":"Potthoff","year":"2009","journal-title":"Proc. Natl. Acad. Sci"},{"key":"10.1074\/jbc.M113.506394_bib45","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1681\/ASN.2008040415","article-title":"Thiazolidinedione-induced fluid retention is independent of collecting duct \u03b1ENaC activity","volume":"20","author":"Vallon","year":"2009","journal-title":"J. Am. Soc. Nephrol"},{"key":"10.1074\/jbc.M113.506394_bib46","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1172\/JCI30335","article-title":"Cardiomyocyte expression of PPAR\u03b3 leads to cardiac dysfunction in mice","volume":"117","author":"Son","year":"2007","journal-title":"J. Clin. Invest"}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820445089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820445089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1074\/jbc.M113.506394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T13:46:44Z","timestamp":1641304004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925820445089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0021925820445089"],"URL":"https:\/\/doi.org\/10.1074\/jbc.m113.506394","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}